摘要
人眼巩膜面积占眼球表面的95％,为经巩膜向眼内给药提供了较大的接触面积和靶向给药的条件.目前经巩膜缓释的装置包括巩膜层间给药,巩膜表面缓释载药盒给药,巩膜表面微药膜给药,巩膜表面离子电渗给药等方法.不同装置和方法各有利弊,巩膜层间给药对巩膜有创伤,缓释药盒需要做得很薄以防止侵蚀结膜,离子电渗给药需要频繁进行等,均是目前需要解决的问题.随着材料生物工程技术的发展,巩膜表面微药膜有广阔的发展前景,有望成为治疗眼后节疾病的理想途径.
The human sclera accounts for 95% of the surface of the eyeball,providing ample contact area which is suitable for targeted trans-scleral ocular drug delivery.Currently there are several tans-scleral sustained-release strategies,including intra-scleral delivery,episcleral delivery,as well as tans-scleral iontophoresis.Different devices and methods have their own advantages and disadvantages,for example,intrascleral delivery is somehow invasive,and episcleral delivery device needs to be made thin to prevent erosion of conjunctiva,iontophoresis needs to be frequently repeated as of its short-term effect.With the development of bio-material engineering technology,episcleral microfilm could become an ideal drug delivery route for posterior segment ocular diseases.
出处
《中华眼底病杂志》
CAS
CSCD
北大核心
2017年第2期213-217,共5页
Chinese Journal of Ocular Fundus Diseases
基金
国家自然科学基金（31271022）
关键词
投药
眼
巩膜
迟效制剂/治疗应用
眼后段
综述
Administration,ophthalmic
Sclera
Delayed-action preparations/therapeutic use
Posterior eye segment
Review
